An In-Depth Study of DOPE:DOPC Liposomes to Maximize Targeted Drug Delivery to Cancer-Associated Cells
January 2023
TLDR DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.
This study explores the use of DOPE:DOPC liposomes to enhance targeted drug delivery for cancer treatment. Four liposome sizes were tested, with 100 nm showing the best cellular uptake. Surface modifications with arginine-like molecules improved targeting of cancer-associated myofibroblasts. Combining doxorubicin and ibuprofen-loaded liposomes showed synergistic effects against macrophages, though more targeting strategies are needed for M2-type macrophages. Additionally, folic acid modification via click chemistry increased uptake by M2-type macrophages. These findings highlight the potential of liposomes for more effective and less toxic cancer therapies.
